Ascentis Independent Advisors Purchases 2,685 Shares of Thermo Fisher Scientific Inc. $TMO

Ascentis Independent Advisors grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 101.9% during the first quarter, HoldingsChannel reports. The institutional investor owned 5,319 shares of the medical research company’s stock after purchasing an additional 2,685 shares during the period. Ascentis Independent Advisors’ holdings in Thermo Fisher Scientific were worth $2,614,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. High Note Wealth LLC increased its holdings in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at $28,000. JPL Wealth Management LLC bought a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $28,000. Beacon Financial Strategies CORP purchased a new position in Thermo Fisher Scientific in the 4th quarter worth about $29,000. Finally, Olistico Wealth LLC bought a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on TMO shares. DZ Bank started coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 price target for the company. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Piper Sandler started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price for the company. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price target for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Finally, Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $605.09.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $522.38 on Monday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The stock has a 50-day simple moving average of $473.17 and a two-hundred day simple moving average of $517.74. The firm has a market capitalization of $194.13 billion, a PE ratio of 28.72, a P/E/G ratio of 2.32 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 52-week low of $403.36 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.